Abstract

Lymphocytic pleurisy is commonly observed in tuberculosis and cancer. Noninvasive biomarkers are needed to distinguish tuberculous pleural effusion (TPE) from malignant pleural effusion (MPE) because current clinical diagnostic procedures are often invasive. We identified immune response biomarkers that can discriminate between TPE and MPE. Fourteen pleural effusion biomarkers were compared in 22 MPE patients and five TPE patients. Of the innate immunity biomarkers, the median levels of interleukin (IL)-1βand interferon-induced protein-10 (IP-10) were higher in TPE patients than in MPE patients (P

Original languageEnglish
Pages (from-to)183-189
Number of pages7
JournalInternational Journal of General Medicine
Volume9
DOIs
Publication statusPublished - Jun 11 2016

    Fingerprint

Keywords

  • Biomarkers
  • Lung cancer
  • Malignant pleural effusion
  • Tuberculous pleural effusion

ASJC Scopus subject areas

  • Medicine(all)

Cite this